2025 -  WEEK 1 - What's New in RWE Research

 

  1. The Transformative Potential of Large Language Models in Mining Electronic Health Records Data: Content Analysis. Wals Zurita AJ et al. JMIR Med Inform. 2025 Jan 2;13:e58457. https://pubmed.ncbi.nlm.nih.gov/39746191/
  1. Geographic atrophy and factors associated with disease progression among Medicare Advantage enrollees. Saundankar V, et al. J Manag Care Spec Pharm. 2025 Jan;31(1):42-52. https://pubmed.ncbi.nlm.nih.gov/39745839/
  1. Disproportionality Analysis of Hepatotoxic and Gastrointestinal Adverse Events Associated With Nintedanib Using the Japanese Adverse Drug Event Report (JADER) Database. Fujiwara M et al. In Vivo. 2025 Jan-Feb;39(1):396-403. https://pubmed.ncbi.nlm.nih.gov/39740899/
  1. Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System. Elshafie S et al. Cancer Med. 2025 Jan;14(1):e70548. https://pubmed.ncbi.nlm.nih.gov/39740002/
  1. A prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the recombinant zoster vaccine in Chinese adults ≥50 years of age. Pang X et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2439031. https://pubmed.ncbi.nlm.nih.gov/39681337/
  1. Retrospective analysis of health and economic burden among commercially-insured individuals diagnosed with invasive meningococcal disease in the United States. Herrera-Restrepo et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2436039. https://pubmed.ncbi.nlm.nih.gov/39681338/
  1. Ravulizumab and Efgartigimod in Myasthenia Gravis: A Real-World Study. Stascheit F et al. Neurol Neuroimmunol Neuroinflamm. 2025 Jan;12(1):e200331. https://pubmed.ncbi.nlm.nih.gov/39602677/
  1. Advanced Approaches to Generating High-validity Real-world Evidence in Asthma. Kilpatrick K et al. Epidemiology. 2025 Jan 1;36(1):20-27. https://pubmed.ncbi.nlm.nih.gov/39589014/
  1. Epidemiology and economic burden of Wilson disease in France: A nationwide population-based study. Fang S et al. J Inherit Metab Dis. 2025 Jan;48(1):e12822. https://pubmed.ncbi.nlm.nih.gov/39582269/
  1. The health-economic impact of urine albumin-to-creatinine ratio testing for chronic kidney disease in Japanese patients with type 2 diabetes. Asahi K et al. J Diabetes Investig. 2025 Jan;16(1):108-119. https://pubmed.ncbi.nlm.nih.gov/39576736/
  1. Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Li J et al. Prev Med. 2025 Jan;190:108180. https://pubmed.ncbi.nlm.nih.gov/39557306/
  1. Initiating continuous glucose monitoring is associated with improvements in glycemic control and reduced health care resource utilization for people with diabetes in a large US-insured population: A real-world evidence study. Norman GJ et al. J Manag Care Spec Pharm. 2025 Jan;31(1):15-24. https://pubmed.ncbi.nlm.nih.gov/39549039/
  1. Global Leadership Initiative in Sarcopenia (GLIS)-defined sarcopenia increases the mortality of esophageal cancer patients after esophagectomy: A Chinese real-world cohort study. Huo Z et al. Nutrition. 2025 Jan;129:112600. https://pubmed.ncbi.nlm.nih.gov/39532033/
  1. Effectiveness and safety of levodopa-entacapone-carbidopa infusion in Parkinson disease: A real-world data study. Santos-García D et al. Eur J Neurol. 2025 Jan;32(1):e16535. https://pubmed.ncbi.nlm.nih.gov/39466665/ 
  1. Post-marketing study design to evaluate the effectiveness of the 9-valent and 4-valent HPV vaccines on serious HPV-related cervical disease in China. Yang Y et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2418168. https://pubmed.ncbi.nlm.nih.gov/39445828/
  1. Effect of a Financial Incentive Scheme for Medication Review on Polypharmacy in Elderly Inpatients With Dementia: A Retrospective Before-and-After Study. Morita T et al. J Patient Saf. 2025 Jan 1;21(1):30-34. https://pubmed.ncbi.nlm.nih.gov/39422523/
  1. Superior benefits of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors for diabetic kidney disease: A cohort study. Chen HL et al. Diabetes Obes Metab. 2025 Jan;27(1):174-183. https://pubmed.ncbi.nlm.nih.gov/39422160/
  1. Real-World Evidence on Prognostic Value of MRD in Multiple Myeloma Using Flow Cytometry. Muronova L et al. Eur J Haematol. 2025 Jan;114(1):155-163. https://pubmed.ncbi.nlm.nih.gov/39390851/
  1. Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data. Litonius K et al. Clin Pharmacol Ther. 2025 Jan;117(1):278-288. https://pubmed.ncbi.nlm.nih.gov/39365028/
  1. Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Shadman M et al. Leuk Lymphoma. 2025 Jan;66(1):44-53. https://pubmed.ncbi.nlm.nih.gov/39352001/
  1. Investigating the Benefit-Risk Profile of Drugs: From Spontaneous Reporting Systems to Real-World Data for Pharmacovigilance. Imbrici P et al. Methods Mol Biol. 2025;2834:333-349. https://pubmed.ncbi.nlm.nih.gov/39312173/
  1. Association Between Gastroesophageal Reflux Disease and Laryngeal Disorders: Real-World Evidence. Lee IY et al. Otolaryngol Head Neck Surg. 2025 Jan;172(1):208-213. https://pubmed.ncbi.nlm.nih.gov/39302108/
  1. NRS2002 score as a prognostic factor in solid tumors treated with immune checkpoint inhibitor therapy: a real-world evidence analysis. Tang W et al. Cancer Biol Ther. 2024 Dec 31;25(1):2358551. https://pubmed.ncbi.nlm.nih.gov/38813753/
  1. Exploring the Link Between Exogenous Thyroid Hormones and Dementia Symptoms: A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System. Zhou J et al. Ann Pharmacother. 2025 Jan;59(1):23-33. https://pubmed.ncbi.nlm.nih.gov/38755964/
  1. Adverse tumor events induced by ranitidine: an analysis based on the FAERS database. Liu M et al. Expert Opin Drug Saf. 2025 Jan;24(1):35-47. https://pubmed.ncbi.nlm.nih.gov/38753437/
  1. Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data. van den Ouweland F et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2315659. https://pubmed.ncbi.nlm.nih.gov/38407186/
  1. Real-World Evidence of the Cambridge Hybrid Closed-Loop App With a Novel Real-Time Continuous Glucose Monitoring System. Newman C et al. J Diabetes Sci Technol. 2025 Jan;19(1):165-168. https://pubmed.ncbi.nlm.nih.gov/37503893/
  1. An Observational Crossover Study of People Using Real-Time Continuous Glucose Monitors Versus Self-Monitoring of Blood Glucose: Real-World Evidence Using Electronic Medical Record Data From More Than 12,000 People With Type 1 Diabetes. Noor N et al. J Diabetes Sci Technol. 2025 Jan;19(1):63-71. https://pubmed.ncbi.nlm.nih.gov/37264642/
  2. Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with bipolar I disorder in the United States. Diaby V et al. J Manag Care Spec Pharm. 2025 Jan;31(1):60-67. https://pubmed.ncbi.nlm.nih.gov/39745847/
  3. Annual prevalence of geographic atrophy and wet age-related macular degeneration among Medicare Advantage enrollees in a US health plan. Saundankar V et al. J Manag Care Spec Pharm. 2025 Jan;31(1):88-94. https://pubmed.ncbi.nlm.nih.gov/39745845/
  4. Predictive modeling to evaluate long-term treatment effectiveness of darvadstrocel in patients with complex perianal fistulas in Crohn's disease. Karki C et al. BMC Gastroenterol. 2024 Dec 30;24(1):479. https://pubmed.ncbi.nlm.nih.gov/39736547/
  5. A comprehensive review of evolving treatment strategies for Dravet syndrome: Insights from randomized trials, meta-analyses, real-world evidence, and emerging therapeutic approaches. Samanta D. Epilepsy Behav. 2025 Jan;162:110171. https://pubmed.ncbi.nlm.nih.gov/39612634/
  6. RWE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 17. Arora P, Ramagopalan SV. J Comp Eff Res. 2025 Jan;14(1):e240212. https://pubmed.ncbi.nlm.nih.gov/39601215/
  7. Artificial intelligence for breast cancer detection and its health technology assessment: A scoping review. Uwimana A et al. Comput Biol Med. 2025 Jan;184:109391. https://pubmed.ncbi.nlm.nih.gov/39579663/
  8. Telehealth delivery of GenerationPMTO in the public mental health system: A pragmatic, noninferiority study. Holtrop K et al. J Marital Fam Ther. 2025 Jan;51(1):e12751. https://pubmed.ncbi.nlm.nih.gov/39523522/
  9. Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real-Life Retrospective Multicentre Cohort Study. Bacsur P et al. Aliment Pharmacol Ther. 2025 Jan;61(2):335-345. https://pubmed.ncbi.nlm.nih.gov/39468719/
  10. Effects of photobiomodulation therapy for acute radiation dermatitis in patients with cancer: A systematic review and meta‑analysis of real-world evidence. Lin YT et al. Radiother Oncol. 2025 Jan;202:110589. https://pubmed.ncbi.nlm.nih.gov/39426526/
  11. An early economic analysis of medical cannabis for the treatment of chronic pain. Marrinan S et al. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan;25(1):39-52. https://pubmed.ncbi.nlm.nih.gov/39415537/
  12. Developing an automated algorithm for identification of children and adolescents with diabetes using electronic health records from the OneFlorida+ clinical research network. Li P et al. Diabetes Obes Metab. 2025 Jan;27(1):102-110. https://pubmed.ncbi.nlm.nih.gov/39344840/
  13. A Real-World Analysis of Weather Variation on Disease Activity and Patient-Reported Outcomes in Psoriatic Arthritis. Joly-Chevrier M et al. J Rheumatol. 2025 Jan 1;52(1):33-37. https://pubmed.ncbi.nlm.nih.gov/39278660/
  14. Comparative Analysis of Post-Authorization Measures for Advanced Medicinal Products Authorized in the European Union and in the United States of America Between 2009 and 2023. Mandslay D et al. Clin Pharmacol Ther. 2025 Jan;117(1):73-93. https://pubmed.ncbi.nlm.nih.gov/39140780/
  15. Long-term outcomes after hypothermic oxygenated machine perfusion and transplantation of 1,202 donor livers in a real-world setting (HOPE-REAL study). Eden J et al. J Hepatol. 2025 Jan;82(1):97-106. https://pubmed.ncbi.nlm.nih.gov/38969242/
  16. A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin. Xu Z et al . Expert Opin Drug Saf. 2025 Jan;24(1):49-57. https://pubmed.ncbi.nlm.nih.gov/38695550/